Manufacturer: Boehringer Ingelheim
Date approved: October 19, 2010
Approved uses: Blood thinner used to prevent strokes
• Internal Bleeding
• Rectal Bleeding
• Increased Risk of Heart Attacks
Related topics: Unsafe Drugs, Coumadin
Common Misspellings: Pradaza, prodaxa, predaxa, pradexa, prodaza, predaza, pradasa, pradexa, pradax, dabagatran, dabigatron, dabigitran
Pradaxa and Internal Bleeding Risk
Pradaxa (generic: Dabigatran), is a blood thinner used to prevent strokes. The medication was created as an alternative to Warfarin, also known as Coumadin. Both drugs may cause internal bleeding in some patients, however, unlike Pradaxa, excessive bleeding caused by Warfarin can be treated with vitamin K. There is no treatment for internal bleeding caused by Pradaxa.
In November 2011, the manufacturer of Pradaxa, admitted than more than 260 deaths were attributed to excessive internal bleeding caused by Pradaxa. Pradaxa has also been linked to an increased risk of heart attacks, according to a January 2012 study published by the Cleveland Clinic, which found that patients have a 33 percent increased risk over other blood thinners or placebos.
Symptoms of internal bleeding caused by Pradaxa include:
• pink or brown urine
• red or black tarry stools
• coughing up or vomiting blood
• bleeding from the gums
• bruises without a known cause
• frequent nosebleeds
• dizziness and lethargy
For additional information about your legal rights regarding Pradaxa’s internal bleeding risk, please contact a LegalView attorney for additional information.